Search company, investor...

Erone Technologies

About Erone Technologies

Developer of therapies for difficult-to-treat and drug-resistant infectious diseases. The company develops a novel FGF-induced immediate-early gene, ER1. The company's research is based on belief that inhibition of the expression or activity of ER1 may inhibit the proliferation and tumorigenic properties of certain cancer cell lines, such as breast and melanoma.

Headquarters Location

University of Newfoundland / Dr. Paterno 300 Prince Phillip Drive

St. John's, Newfoundland and Labrador, A1B 3V6,

Canada

(709)777-7012

Missing: Erone Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Erone Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Erone Technologies Frequently Asked Questions (FAQ)

  • Where is Erone Technologies's headquarters?

    Erone Technologies's headquarters is located at University of Newfoundland / Dr. Paterno, St. John's.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.